- Home
- ATNM
as 07-26-2024 4:00pm EST
Actinium Pharmaceuticals Inc is a biopharmaceutical company engaged in the development of radiotherapies for patients with cancers lacking effective treatment options. The company's proprietary technology platform utilizes monoclonal antibodies to deliver radioisotopes directly to cells of interest to kill those cells safely and effectively. Its product candidates are Iomab-B, an antibody-drug construct containing iodine 131 (I-131), used for hematopoietic stem cells transplantation in various indications and Actimab-A, an antibody-drug construct containing actinium 225 (Ac-225), currently in human clinical trials for acute myeloid leukemia.
| Founded: | 2000 | Country: | United States |
| Employees: | N/A | City: | NEW YORK |
| Market Cap: | 227.8M | IPO Year: | N/A |
| Target Price: | $25.60 | AVG Volume (30 days): | 282.5K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 6 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.71 | EPS Growth: | N/A |
| 52 Week Low/High: | $4.00 - $10.24 | Next Earning Date: | 08-12-2024 |
| Revenue: | $81,000 | Revenue Growth: | -10.00% |
| Revenue Growth (this year): | 138.42% | Revenue Growth (next year): | 30021.18% |
Latest Actinium Pharmaceuticals Inc. (Delaware) News
ATNM Breaking Stock News: Dive into ATNM Ticker-Specific Updates for Smart Investing
MT Newswires
a day ago
Actinium Pharmaceuticals Gets FDA Approval for Sickle Cell Disease Treatment Study
PR Newswire
a day ago
Actinium Announces FDA Clearance of Iomab-ACT Targeted Conditioning IND Application for Sickle Cell Disease Patients Undergoing Bone Marrow Transplant in Collaboration with Columbia University
PR Newswire
a day ago
Actinium Pharmaceuticals to Present at the 3rd Annual Targeted Radiopharmaceuticals Summit US
Zacks
a month ago
Is Actinium Pharmaceuticals (ATNM) Outperforming Other Medical Stocks This Year?
Newsfile
a month ago
Treatment of Blood Cancers - Biopharma Companies Building out their Pipeline of Solutions
Newsfile
a month ago
Biopharma Stocks Quest for Solutions for Acute Myeloid Leukemia (AML)
PR Newswire
a month ago
Actinium Presents First Ever Data Demonstrating Actimab-A in Combination with Leading Menin Inhibitors Leads to Anti-Tumor Control and Potent Leukemic Cell Killing in Preclinical Acute Myeloid Leukemia Models at the 2024 EHA Congress
PR Newswire
a month ago
Actinium Highlights Oral Presentation at EHA 2024 Annual Congress Featuring Improved Outcomes in TP53 Positive Patients Receiving Iomab-B in the Phase 3 SIERRA Trial
Compare ATNM vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ATNM Actinium Pharmaceuticals Inc. (Delaware) - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.